After a three-year quarantine from the deadliest global pandemic of the last century, ASTES is organizing to gather all health professionals in Tirana, The 6th Albanian Congress of Trauma and Emergency Surgery(ACTES 2022) on 11-12 November 2022, with the topic Trauma & Emergency Surgery and not only...with the aim of providing high quality, the best standards, and the best results, for our patients ...ACTES 2022 is the largest event that ASTES (Albanian Society for Trauma and Emergency Surgery) has organized so far with 230 presentations, and 67 foreign lecturers with enviable geography, making it the largest national and wider scientific event.The scientific program is as strong as ever, thanks to the inclusiveness, where all the participants with a mix of foreign and local lecturers, select the best of the moment in medical science, innovation, and observation.The scientific committee has selected all the presentations so that the participants of each medical discipline will have something to learn, discuss, debate, and agree with updated methods, techniques, and protocols.I hope you will join us on Friday morning, and continue the journey of our two-day event together.

No abstract

No abstract

Background: Gastric cancer (GC) is the fourth most common cancer in Albania. Gastric cancer has a 5-year survival rate as low as 30%. The expression of HER2 in gastric cancer has brought a new alternative treatment for patients. Materials and method: 192 patients were analyzed retrospectively, with primary GCs for HER2 overexpression by IHC and Dual SISH in equivocal cases. This was compared with the results of HER2 in gastric patients in surgical specimens and endoscopic biopsies and there is a correlation between gender, age, stage, and type of the histopathologic gastric cancer diagnosis. Results: Examinations were made by immunohistochemistry for HER2 in 73.4% (141 cases) of surgical specimens and 26.5% of endoscopic biopsies: 18.4% (26 cases) and 15.7% (8 cases) were HER2 3+, respectively. HER2 overexpression (3+) was detected in 17.7% (34 cases). HER2 Equivocal (2+) was detected in 24.5% (47 cases). 17.8%, 14%, and 4.7% were respectively intestinal type, diffuse, signet ring, and the rest adenocarcinoma NOS. GC prevailed in the group aged 61-70 yrs. (31.70%), followed by 51-60 yrs. (25%), 22.9% in 71-80-yrs. 20 cases analyzed by SISH, showed HER2 amplification in 40% (8cases). Economical restrictions and problems with the preanalytical phase made it impossible to evaluate by SISH all 20 cases. Conclusion: 17.7% of Albanian patients with primary GC were HER2-positive on IHC. There is no difference in biopsy and surgical specimen results. Economic restrictions can influence the results.